Physician profile
Radhakrishna Kukkillaya
NPI 1114981156
$3,424.22
in general payments reported to CMS, 2019-2025
31 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $588 · 2021: $878 · 2022: $385 · 2023: $434 · 2024: $399 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,072.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $460.16 | 2019-2023 | |
| Novo Nordisk INC | $399.60 | 2019-2022 | |
| Pfizer INC. | $235.96 | 2019-2021 | |
| Abbvie INC. | $183.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.50 | 2019-2023 | Relistor |
| Abbott Laboratories | $114.04 | 2021-2025 | Freestyle Libre 2 |
| Sunovion Pharmaceuticals INC. | $95.84 | 2021-2022 | |
| Amgen INC. | $79.64 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.93 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $51.07 | 2021-2024 | Xarelto |
| Shield Therapeutics INC | $50.95 | 2023-2024 | Accrufer |
| Esperion Therapeutics, INC. | $46.87 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.49 | 2020-2021 | |
| Daiichi Sankyo INC. | $36.00 | 2023 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $34.10 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $30.71 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $29.90 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Vifor Pharma, INC. | $25.03 | 2020-2023 | Veltassa |
| Lexicon Pharmaceuticals, INC. | $24.57 | 2023 | Inpefa |
| Nevro Corp. | $23.50 | 2021 | |
| Melinta Therapeutics, LLC | $19.73 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Insulet Corporation | $19.43 | 2024 | Omnipod |
| Lilly USA, LLC | $19.29 | 2022 | |
| Si-Bone, INC. | $19.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.80 | 2022 | |
| Astellas Pharma US INC | $15.67 | 2023 | Veozah |
| Scpharmaceuticals INC. | $15.60 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2020 | |
| Redhill Biopharma INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radhakrishna Kukkillaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.